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Abstract Statins, such as simvastatin, and ACE in-
hibitors (ACEis), such as ramipril, are standard thera-
pies for the prevention and treatment of cardiovascu-
lar diseases. These types of drugs are commonly ad-
ministered together. More recently, angiotensin II type
1 receptor (AT1R) antagonists, such as candesartan
cilexetil (candesartan), have been used in the place of,
or in combination with, ACEis. Here, we investigated
the effects of simvastatin and ramipril single and com-
bination therapy, and candesartan treatment on the
lifespan of isocalorically fed, long-lived, B6C3F1
mice. Males were used for their relative endocrine
simplicity and to minimize animal usage. The drugs
were administered daily in food. The simvastatin and
ramipril combination therapy significantly increased
the mean and median lifespan by 9 %. In contrast,
simvastatin, ramipril, or candesartan monotherapy
was ineffective. All groups consumed the same num-
ber of calories. Simvastatin, alone or administered
with ramipril, decreased body weight without
changing caloric consumption, suggesting it may alter
energy utilization in mice. Combination therapy ele-
vated serum triglyceride and glucose levels, consistent
with altered energy homeostasis. Few significant or
consistent differences were found in mortality-
associated pathologies among the groups. Simvastatin
treatment did not reduce normal serum cholesterol or
lipid levels in these mice, suggesting that the longev-
ity effects may stem from the pleiotropic, non-choles-
terol-related, effects of statins. Together, the results
suggest that statins and ACEis together may enhance
mouse longevity. Statins and ACE inhibitors are gen-
erally well-tolerated, and in combination, they have
been shown to increase the lifespan of normotensive,
normocholesterolemic humans.
Keywords Statins . ACE inhibitors . Angiotensin II
receptor antagonists . Life span . Longevity
Introduction
Cardiovascular disease is the leading cause of mor-
bidity and mortality worldwide (World Health
Organization 2004). Statins [3-hydroxy-3-methylglu-
taryl coenzyme A (HMG-CoA) reductase inhibitors],
such as simvastatin, reduce the biosynthesis of the
isoprenoids used for cholesterol biosynthesis
(Spindler et al. 2012a; Edwards and Ericsson 1999).
Statins have been shown by meta-analyses to reduce
cardiovascular death by 20–30 % (Taylor et al. 2011).
These health benefits appear to stem from both
AGE (2016) 38:379–391
DOI 10.1007/s11357-016-9948-4
S. R. Spindler (*) : P. L. Mote
Department of Biochemistry, University of California at Riverside,





Department of Statistics, University of California at Riverside,
Riverside, CA 92521, USA
e-mail: james.flegal@ucr.edu
/Published online: 16202 September
reduced serum cholesterol levels (Ludman et al.
2009) and reduced protein isoprenylation [e.g.,
(Spindler et al. 2012a)]. The pleiotropic effects of
reduced isoprenoid biosynthesis are independent of
their effects on cholesterol levels (Spindler et al.
2012a; Ludman et al . 2009). For example,
simvastatin’s non-cholesterol-related, pleotropic ef-
fects increase the lifespan and health span of Dro-
sophila by decreasing protein isoprenylation
(Spindler et al. 2012a).
ACEis, such as ramipril, are used as antihyperten-
sives (Crowley et al. 2012). They reduce the biosynthe-
sis of angiotensin and thereby reduce the activity of the
AT receptors, most importantly, AT1R [reviewed in (te
Riet et al. 2015)]. In the vessel wall, AT1R activation
induces vasoconstriction, endothelial dysfunction, in-
flammation, growth, and remodeling [reviewed in (te
Riet et al. 2015)]. Reduced AT1R signaling reduces
blood pressure and the incidence of stroke, diabetic
kidney disease, congestive heart failure, diabetes
mellitus, and atrial fibrillation [reviewed in (Strauss
and Hall 2016)]. Until recently, angiotensin II receptor
antagonists (ARAs) were thought to have effects very
similar to those of ACEis (Yusuf et al. 2003; Odagiri
et al. 2014). More recent meta-analyses suggest that
ACEis, but not ARAs, reduce myocardial infarction
and all-cause mortality in patients with hypertension
(van Vark et al. 2012; Strauss and Hall 2016). The
reasons for these differences are unclear at present (te
Riet et al. 2015).
There are several reports that combined statin and
ACEi treatment in humans additively improves some
mortality and other health-related outcomes (Chae et al.
2011; Zoja et al. 2010; Abdel-Zaher et al. 2012; Faglia
et al. 2014). In mice, there are several reports that ACEi
treatment increases lifespan (Ferder et al. 1993; Basso
et al. 2007; Santos et al. 2009). Others reports indi-
cate ACEi or statin monotherapy have no effect on
lifespan (Miller et al. 2011; Harrison et al. 2009). None
of these studies report food consumption, body weight,
or end-of-life pathologies. In addition, we found no
studies reporting the effects of combined statin and
ACEi treatment on animal lifespan. For these reasons,
we investigated the effects of statin, ACEi, and an ARA
monotherapy, and statin and ACEi combination therapy
on the lifespan of robust, F1 male mice. The effects of
these treatments on food consumption, body weight,




Male, C3B6F1 mice were treated with simvastatin and
ramipril individually and in combination, and with
candesartan (Table 1). The rationale for the dosages used
is presented in the Discussion. The mouse cohorts and
numbers of mice in each group are shown in Table 2. The
mice in thecontrol and treatmentgroupswere fed the same
number of calories, and food consumptionwasmonitored
daily. Combined treatment with simvastatin and ramipril
together (SimRam) significantly extended themedian and
mean lifespanof themicebyapproximately9%, from983
to 1068 days (Mantel-Cox P = 0.050, Gehan-Breslow-
Wilcoxon P = 0.009; Fig. 1a). TheMantel-Cox test gives
equal weight to all time points, while theGehan-Breslow-
Wilcoxon test gives more weight to deaths at early time
points. Monotherapy with simvastatin or ramipril did not
significantly change lifespan (Fig. 1b, c). Likewise, the
ARA, candesartan, did not alter lifespan (Fig. 1d). Thus,
suppression of AT1R signaling is not sufficient to induce
the lifespan increase seen in the SimRam-treated mice.
Mice fed food containing simvastatin and candesartan
together ate so little of the food, even when it contained
bacon flavoring, that the studies had to bediscontinued for
humane reasons.
The studies reported here are from two lifespan stud-
ies, we term cohorts 1 and 2, each composed of 2400
mice. The cohorts 1 and 2 control groups were made up
of 297 and 304 mice, respectively (Table 2). All the
treatment groups were composed of 36 mice. This un-
balanced statistical design allowed the efficient evalua-
tion of a larger number of treatments than would be
possible using a balanced design (Jeske et al. 2014).
Table 1 Treatment groups and dosages used








47 and 188 5.0 and 20
Ramipril 47 5.0
Candesartan 9.42 1.0
a The rationale for the dosages used are in Discussion
b Calculated assuming a 39-g mouse, which is the approximate
mean body mass throughout the treatment period (Fig. 3a, b)
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The close equivalency of the two studies is illustrated in
Fig. 2, where the survival of the control groups is plotted
as a function of age. The median survival of the two
cohorts was statistically indistinguishable, 983 and
995 days, for cohort 1 and cohort 2, respectively. The
large sample sizes provide a high level of statistical
power.
Drug effects on food intake and body weight
All mice were fed daily, and the groups consumed the
same number of calories (Fig. 3a, b). The drugs were
cold packed in the AIN-93M diet and fed in measured
amounts beginning at 12 months of age. Uneaten food
was noted daily, and the next day’s aliquot adjusted to
maintain the daily allotment of calories. Food consump-
tion was essentially unchanged throughout the study,
indicating that the treatments did not produce Bvolun-
tary^ caloric restriction (CR).
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Fig. 1 Effects of simvastatin,
ramipril, and candesartan
monotherapy and SimRam
treatment on the lifespan of mice.
The effects of SimRam therapy
are shown in a (open circles),
while the effects of simvastatin
monotherapy are in b (open
circles). The effects of ramipril
monotherapy are shown in c
(open circles). The lifespan of
candesartan treated mice (open
circles) is shown in d (open
circles). The control group is
shown in all panels as filled
circles. Feeding of the drugs

























Fig. 2 The lifespan of the cohort 1 control mice (closed circles) is
plotted with the lifespan of the cohort 2 control mice (open circles)
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As observed previously, the mean weight estimates
became increasingly unstable as days on diet increased,
due to a declining number of survivors (Spindler et al.
2013a; Spindler et al. 2013b). A transient reduction in
food consumption by the SimRam group at 1125 days
(3 years) of age was related to late-life pathology in 2 of
the 12 mice remaining at that time (Fig. 3a). When these
mice died, the anomaly resolved. The anomaly in food
consumption did not have an effect on mean body mass
because body weights were measured before and after
the event.
Despite eating the same number of calories, the
SimRam-treated mice (SimRam mice) weighed signifi-
cantly less than the controls, according to a BIC model
selection criteria, a likelihood ratio test using a level of
significance of 0.01, and an AIC selection criteria
(Fig. 3a; Table 3). Ramipril had no effect on body
weight (Fig. 3b; Table 4). Together, these data are con-
sistent with the idea that simvastatin disrupts energy
homeostasis in mice (see Discussion).
Mortality-related pathologies
The necropsy results are summarized in Tables 5
through 8. Few significant differences were found in
the pathologies of the control and treatment groups
(Tables 5 and 6). There was a significant increase in
benign lung tumors in the simvastatin and combined
statin treatment groups, and an increase in hemorrhagic
diathesis in the SimRam and combined statin treatment
groups (Table 5). No differences were found in the mean
mass of the liver tumors or total mass of liver tumors per
mouse between the control and treated groups (Tables 7
and 8). These differences from control do not appear to
have had an impact on survival. Neither the increase in
benign lung tumors nor that in hemorrhagic diathesis
was consistently associated with altered lifespan.
Blood chemistries
SimRam treatment produced a significant increase in
serum glucose concentrations (P < 0.001) and a non-
significant doubling in triglyceride concentrations
(Table 9). Ramipril monotherapy produced almost a
doubling in serum triglycerides (P < 0.01). Ramipril
treatment also may have elevated total serum choles-
terol, HDL, and LDL, although these changes were
only marginally significant. Forty percent CR signif-
icantly decreased body weight and serum LDL, while
tripling the level of serum triglycerides (P = 0.028;
Table 9).























































































Fig. 3 Body weights and food consumption of the mice shown in
Fig. 1a, b, d. Shown are the body weights of the control (open
circles), simvastatin monotherapy (upward pointing open trian-
gles), SimRam (downward pointing open triangles), and
candesartan (open squares)-treated mice. Caloric consumption
with respect to the number of calories fed is shown for control
(filled circles), simvastatin (upward pointing filled triangles),
SimRam (downward pointing filled triangles), and candesartan-
treated mice (filled squares). The statistical significance of these
data versus the weights of the control group is shown in Table 3;
and discussion in Results. Shown in b are the body weights of the
control (closed circles) and ramipril monotherapy (open circles)-
treated mice (Fig. 1c). Also shown is caloric consumption for the
control (closed upward pointing triangles) and ramipril-treated (open
upward pointing triangles) mice. The ramipril-treated mice were
not significantly different in weights or food consumption from the
control mice at any time (Table 4; and discussion in Results)
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Endogenous drug levels
Multiple attempts were made to measure the level of
simvastatin in the serum of treated mice (Materials and
methods). Multiple extraction techniques and liquid
chromatography-tandem mass spectrometry (LC-MS/
MS) were utilized without success, likely due to the
low levels of the drug in serum, and the limited quanti-
ties of serum that can be obtained from mice. Similar
human studies typically utilize 40 mls of plasma per
assay (Zhao et al. 2000). Approximately 3 ml of serum
is required to measure serum ramipril concentrations
(Lu et al. 2006). Nevertheless, the dosages of the drugs
administered to these mice were shown previously to
produce well-defined therapeutic endpoints in multiple
published mouse studies, including a study from our
laboratory (see Drug dosages, in Discussion).
Discussion
The work presented here shows that treatment with
simvastatin and ramipril together extended the lifespan
of isocalorically fed, long-lived mice, while monother-
apy with either drug alone was ineffective. Candesartan
administration was also ineffective at changing lifespan.
Previous studies
Lifespan extension by SimRam and the decrease in
body mass induced by simvastatin in mice are novel
results. Our results are consistent with those of others
which failed to find a change in lifespan with oral
simvastatin treatment (Miller et al. 2011). The decrease
in body weight found in our study has not been reported
previously, probably because previous studies adminis-
tered food ad libitum and body weights were not
reported.
The lifespan effects of agents which reduced AT1R
signaling in rodents have been the subject of conflicting
reports (Spindler 2012). Enalapril, an ACEi, has been
reported to both increase (Ferder et al. 1993; Basso et al.
2007; Santos et al. 2009) and to have no effect (Harrison
et al. 2009) on rodent lifespan. An early study by Ferger
et al. found that a greater percentage of mice lived to
24 months of age when enalapril was present in their
drinking water (Ferder et al. 1993). However, the treated
mice were much heavier than the control mice, and the
mean lifespan of the control mice was ∼548 days, which
is short relative to that reported by others for this strain
(∼664 days) (Kahn 1975). Basso et al. reported that rats
treated with enalapril or an AT1R antagonist lived longer
than controls (Basso et al. 2007). But, few rats appear to
have been involved in this lifespan study, and their actual
numbers were not reported. Further, the enalapril-treated
rats had lower body weights throughout the study, sug-
gesting that theremay have been an unintended CR effect
on survival for this group. Santos et al. reported that more
enalapril-treated rats lived to 26 months of age than did
their chow-fed littermates (Santos et al. 2009). However,
both food intake and body weight were significantly
reduced by the drug, suggesting the possibility of an
unintended CR-related survival benefit. In the studies of
Harrison et al., neither body weight nor food intake was
reported (Harrison et al. 2009).
Table 3 Summary of the statistical analysis of mouse group weights (Fig. 3a) using BIC model selection removing each diet individually
Diet df AICa BIC Χ Chi df Pr(χ2df > X)
Control 16 21,977 22,079
Simvastatin 14 21,975 22,065 2.3197 2 0.3135
SimRam 14 22,005 22,095 32.525 2 8.656e-08
Candesartan 14 21,978 22,068 5.5716 2 0.06168
df degrees of freedom, AIC Akaike’s Information Criterion, BIC Bayesian Information Criterion, Chi df chi-squared degrees of freedom
aValues indicative of significance are shown in bold for convenience
Table 4 Summary of the statistical analysis of mouse group
weights in (Fig. 3b) using BIC model selection
Diet df AIC BIC Χ Chi df Pr(χ2df > X)
Control 12 18,615 18,690
Ramipril 10 18,613 18,675 1.7653 2 0.4137
df degrees of freedom, AIC Akaike’s Information Criterion, BIC
Bayesian Information Criterion, Chi df chi-squared degrees of
freedom
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The synergistic effects of simvastatin and ramipril
on lifespan
Statins and ACEis are often administered together
(DeWilde et al. 2008), and combined treatment addi-
tively improves some mortality and other health-
related outcomes (Chae et al. 2011; Zoja et al. 2010;
Abdel-Zaher et al. 2012; Faglia et al. 2014). For
example, diabetic patients with critical limb ischemia
had better life expectancies with ACEi and statin
therapy combined than when they were treated with
either therapy alone (Faglia et al. 2014). Hyperten-
sive, hypercholesterolemic rats and humans undergo-
ing combined statin and ramipril therapy have greater
increases in serum nitric oxide and greater reductions
in malondialdehyde and high-sensitivity C-reactive
Table 6 Necropsy results for the ramipril-treated and control mice shown in Fig. 1c
Organ Pathology Dietary treatment
Control (n = 36)a Ramipril (n = 36)
No.b (%)c No. (%) P valued
Spleen Enlarged/tumorous 19 70.4 16 59.3 0.569
Liver Hemangioma 0 0.0 0 0.0 1.000
Enlarged/fatty liver 1 3.7 1 3.7 1.000
Tumor 18 66.7 11 40.7 0.101
Intestine Tumor 2 7.4 1 3.7 1.000
Lung Tumor 19 70.4 12 44.4 0.098
Penis Necrosed/inflamed 0 0.0 1 3.7 1.000
Seminal vesicle Enlarged 2 7.4 1 3.7 1.000
Bladder Distended 1 3.7 1 3.7 1.000
Kidney Enlarged/tumorous 2 7.4 1 3.7 1.000
Thymus Enlarged 5 18.5 7 25.9 0.7445
Skin/abdominal cavity Fibroma 4 14.8 6 22.2 0.7277
Body cavity Hemorrhage 7 25.9 9 33.3 0.7664
Thorax only Hemorrhage 8 29.6 3 11.1 0.1751
Body cavity and thorax Hemorrhage 15 55.6 12 44.4 0.5867
aNumber of necropsied mice in each group. All deceased mice were necropsied. The necropsied control mice were chosen to approximate
the ages at death of the ramipril-treated mice
b The number of necropsied mice with each pathology
c The percent of the necropsied mice in each group with the indicated pathologies
d Fisher’s exact test was utilized to investigate the association between the pathologies and ramipril treatment. The P values are two-sided.
No significant differences were found
Table 7 Tumor mass for liver tumors reported in Table 5
Liver tumors Control (n = 72) Simvastatin (n = 35) SimRam (n = 36) Candesartan (n = 36)
Mean mass of each
tumor ± SEM (g)a
1.09 ± 0.18b 1.35 ± 0.31 (P = 0.684)c 1.35 ± 0.37 (P = 0.569) 0.68 ± 0.15 (P = 0.119)
Tumor mass/number of
mice with tumors (g)
1.1 1.7 1.3 0.5
a Tumor mass was calculated as (π/6) × l × w × h × 1.0 g, where l is the length,w is the width, and h is the height of each tumor; 1 cm3 = 1 g
bMean plus or minus the standard error of the mean
c Significance of the difference in median tumor mass calculated using the Mann–Whitney U test implemented in Minitab. No significant
differences were found
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protein levels, and reduced systolic and diastolic
blood pressure than those treated with either drug
alone (Abdel-Zaher et al. 2012). Combined ACEi
and statin therapy produces an additive reduction in
breast cancer recurrence versus monotherapy with
either drug alone (Chae et al. 2011). Likewise, rats
with overt diabetic nephropathy who receive com-
bined statin and ACEi therapy have greater reductions
in renal proteinuria than with monotherapy using ei-
ther drug type (Zoja et al. 2010).
A number of mechanisms for the synergistic ef-
fects of statins and ACEi on mouse lifespan appear
plausible.
Energy homeostasis The decrease in body weight pro-
duced by SimRam treatment in the absence of a de-
crease in food consumption suggests that the drugs
produced a change in metabolic energy disposition
(Tables 3 and 4). Evidence for this effect can be found
in the approximate doubling of blood glucose concen-
trations and nonsignificant doubling of serum triglycer-
ides (Table 9). These results suggest that SimRam treat-
ment decreased insulin sensitivity. Statins increase the
risk of type 2 diabetes and decrease insulin sensitivity
and insulin secretion in humans (Sattar et al. 2010;
Cederberg et al. 2015). In our mice, ramipril treatment
significantly increased serum triglyceride levels,
Table 8 Tumor mass for liver tumors reported in Table 6
Liver tumors Control (n = 36) Ramipril (n = 36)
Mean mass of the tumors ± SEM (g)a 0.88 ± 0.12b 0.67 ± 0.19 (P = 0.132)c
Liver tumor mass/number of mice with tumors 1.2 1.2
a Tumor mass was calculated as in Table 7
bMean plus or minus the standard error of the mean
c Significance of the difference in median tumor mass calculated using the Mann–Whitney U test implemented in Minitab. No significant
differences were found
Table 9 Glucose and lipid profiles of blood serum from control, simvastatin, Sim/Ram, ramipril, and CR-treated mice
BW TC HDL LDL TG NEFA Glu
(g) (mg/dL) (mg/dL) (mg/dL) (mg/dL) (mEq/L) (mg/dL)
Control 41.9 ± 3.2b 183.1 ± 40.0 175.5 ± 36.9 22.4 ± 8.0 40.8 ± 13.2 0.905 ± 0.157 128.4 ± 13.6
Simvastatin 42.8 ± 2.2 162.9 ± 32.5 162.4 ± 21.7 18.7 ± 7.9 42.5 ± 15.4 1.032 ± 0.231 146.2 ± 40.4
Sim P valuea 0.609 0.404 0.518 0.481 0.853 0.342 0.403
Sim/Ram 39.9 ± 5.0 168.2 ± 25.3 166.9 ± 14.7 20.4 ± 9.7 80.9 ± 36.1 0.901 ± 0.269 241.4 ± 21.6
Sim/Ram P value 0.489 0.500 0.648 0.726 0.067 0.980 0.000
Ramipril 44.16 ± 1.8 231.7 ± 24.1 220.7 ± 23.4 33.9 ± 8.7 70.7 ± 11.1 1.051 ± 0.235 130.2 ± 55.4
Ramipril P value 0.210 0.060 0.060 0.065 0.006 0.292 0.947
40 % CR 33.9 ± 2.7 159.3 ± 7.4 141.0 ± 28.7 9.7 ± 2.6 130.8 ± 58.2 0.729 ± 0.106 122.0 ± 10.6
40 % CR P value 0.004 0.257 0.143 0.027 0.028 0.076 0.432
Five male, B6C3F1 mice in each treatment group were 448 days of age at the time they were bled by cardiac puncture. The treated mice
received each drug or combination of drugs in their food for 99 days. The 40 % CR group was shifted to 11 kcal/day/mouse of AIN-93 M
20% Restricted Diet (Diet no. F06298, Bioserv) for 2 weeks, and thereafter to 7.46 kcal/day of AIN-93M 40% restricted diet (diet number
F05314, Bio-Serv). The stepped reduction in calories reduces stress-induced mortality during the period of initial weight loss. The total time
on a CR diet was 99 days. The control mice were fed control diet for the same period of time. Procedures and husbandry were as described
for the other mice in this report. Glucose measurements were made using the FreeStyle Lite Blood Glucose Monitoring System (Abbot
Diabetes Care, Alameda, CA). Other blood tests were performed by the Comparative Pathology Laboratory, University of California, Davis
BW body weight, CR calorically restricted, Glu glucose, HDL high-density lipoprotein, LDL calculated low density lipoprotein, NEFA
nonesterified fatty acid, TC total cholesterol, TG triglycerides
aP values were determined using a two-tailed t test. Each P value is applicable to the measurements immediately above it
bMean ± standard deviation. Values indicative of significance are shown in bold for convenience
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suggesting that this drug also interfered with metabolic
control (Table 9). Ramipril treatment has been reported
to elevate serum triglycerides in hypertensive, non-
insulin-dependent diabetic patients (Schnack et al.
1996). These combined data suggest that SimRam treat-
ment disrupted metabolic control combinatorially in the
mice, inducing hyperglycemia and hyperlipidemia.
The association of hyperglycemia and hyperlipid-
emia with enhanced lifespan seems counterintuitive in
that increased insulin sensitivity is most often associated
with longer lifespan (Spindler 2010; Bartke et al. 2013).
However, rapalogues are robust extenders of mouse
lifespan, and they produce hyperglycemia, glucose in-
tolerance, hypertriglyceridemia, and hypercholesterol-
emia (Miller et al. 2011; Cunningham et al. 2007). In
our study, 40 % CR also produced hypertriglyceridemia
(Table 9). Like treatment with rapalogues, 40 % percent
CR can increase the lifespan of B6C3F1 mice (Spindler
et al. 2013b). Thus, SimRam treatment may engage
some of the same longevity pathways as rapalogues
and CR.
Protein isoprenylation Cholesterol levels were not re-
duced in the SimRam- or simvastatin-treated mice.
Thus, the lifespan effects of SimRam were most likely
due to the pleiotropic effects of statins (Table 9). Sim-
vastatin increased the lifespan of Drosophila by reduc-
ing protein isoprenylation, a non-cholesterol-related ef-
fect (Spindler et al. 2012a). Many of the pleiotropic
benefits of statins are mediated by reduced
isoprenylation of specific small GTP-binding proteins,
which results in reduced signaling growth factor recep-
tors (Ludman et al. 2009; Zeichner et al. 2012). The
dose of simvastatin used here reduces Ras protein
isoprenylation in the B6C3F1 mice used for the present
lifespan study (Spindler et al. 2012a). Reduced growth
factor signaling is associated with increased lifespan in
species as phylogenically diverse as flies and mice
(Spindler 2010; Spindler et al. 2012b; Bartke et al.
2013).
AT1R signaling The effects of ramipril on the longevity
effects of SimRam may have been the result of reduced
AT1R signaling, especially in the vessel wall (te Riet
et al. 2015). Decreased AT1R signaling should reduce
NAD(P)H oxidase activity in multiple cell types of the
vessel wall and elsewhere (Montezano and Touyz 2014;
Virdis et al. 2004). This decrease would reduce reactive
oxygen species and signaling throughmitogen-activated
protein kinases, tyrosine kinases, phosphatases, calcium
channels, and redox-sensitive transcription factors
(Montezano and Touyz 2014; Virdis et al. 2004). Thus,
ACEis reduce cell growth and migration, vascular re-
modeling, and proinflammatory gene expression (te
Riet et al. 2015; Zhao et al. 2014; Wu et al. 2014;
Muller et al. 2013).
Tumors Upon necropsy of the simvastatin and SimRam
groups, we found an increase in the number of benign
lung tumors, but no change in other tumor types
(Table 5). There is a large population-based study which
found that mortality from 13 types of human cancer was
reduced by statins (Nielsen et al. 2012). Other studies
performed with cultured cells or chemically induced or
engrafted human tumor models in mice seem to support
this study (Zeichner et al. 2012). However, the behavior
of induced, transplanted, and cultured model tumor cells
in mice does not necessarily predict the behavior of
spontaneous tumors in vivo (Day et al. 2015; Marx
2014). Also, the results of Nielsen et al. have yet to be
confirmed in other cohorts. In any case, we found few
effects of simvastatin and SimRam on cancer incidence
in this study.
Drug dosages
We utilized drug dosages previously reported to induce
well-defined therapeutic endpoints in mice. Simvastatin
was administered orally at 20 mg drug/kg bw/day
(Table 1). This dose reduces the isoprenylation of spe-
cific Ras superfamily members in the liver of the F1
mouse used in the present study and suppresses the
growth of K562 chronic myelogenous leukemia cell
xenografts in nude mice (Oh et al. 2012; Spindler et al.
2012a). This dose is approximately half that which
relieves diabetic complications in db/db mice
(Kolavennu et al. 2008). Serum simvastatin levels are
too low to be accurately quantified in mice using liquid
chromatography tandem mass spectrometry (LC-MS/
MS) (Spindler et al. 2012a).
Ramipril was administered at 5 mg/kg bw/day
(47 mg drug/kg diet). This dose inhibits multiple mea-
sures of atherogenesis in apolipoprotein E-deficient
mice (Hayek et al. 2002). Half of this dose reduces
pressure overload-induced cardiac hypertrophy and car-
diomyocyte and noncardiomyocyte proliferation in
male mice (Muller et al. 2013). We did not attempt to
measure the serum levels of angiotensin isoforms since
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ACE escape often decouples the blood levels of angio-
tensin isoforms and aldosterone (which may rise) from
the inhibition of their phenotypic activities (which re-
main inhibited) during long-term ACEi treatment (te
Riet et al. 2015). Candesartan was administered at
1 mg/kg bw/day (9.42 mg drug/kg diet). This dose
suppresses the growth of human bladder carcinoma cell
xenografts in nude mice by 42 % (Kosugi et al. 2009)
and increases the survival of a mouse model of inherited
dilated cardiomyopathy (Odagiri et al. 2014). The dos-
ages used were chosen for the likelihood that they would
be both safe and effective at producing a relevant bio-
logical response over the lifespan of a treated mouse.
Conclusions
Combined simvastatin and ramipril treatment signifi-
cantly increases the lifespan of B6C3F1 mice. Neither
drug alone nor an AT1R antagonist alone significantly
altered lifespan. The increase in lifespan in the absence
of a change in serum cholesterol or lipoprotein levels
recalls studies in Drosophila showing that statin mono-
therapy can increase lifespan by decreasing protein
farnesylation and geranylgeranylation (Spindler et al.
2012a). Thus, simvastatin and ramipril combined treat-
ment may extend lifespan by reducing growth factor
signaling in mice.
Materials and methods
Mouse lifespan and food consumption
Two cohorts of 2400 male B6C3F1 mice were utilized
for these studies. The mice were unmated. B6C3F1
mice are a cross between C57BL/6NHsd inbred females
and C3H/HeNHsd inbred males. Cohort 1 (Harlan
Breeders) included 297 control mice and groups of 36
treated mice. The mice described here were treated with
simvastatin, simvastatin and ramipril together, and
candesartan at the concentrations shown in Table 1.
Cohort 2 (Charles River Laboratories) included a group
of 304 control mice and groups of 36 treated mice. One
of these groups was treated with ramipril at the concen-
tration shown in Table 1. Other of our reports describe
results obtained for other treatment groups in these
cohorts (Spindler et al. 2013a, b, 2014a, b, 2015;
Martin-Montalvo et al. 2013). After weaning, mice in
both cohorts were fed mouse chow (Diet # 5001, Purina
Mills, Richmond, IN) ad libitum until random assign-
ment to groups at 12 months of age. Animal husbandry
and experimental design were as described in detail
elsewhere (Spindler et al. 2013a, 2013b). Briefly, con-
trol mice were shifted at 12 months of age to daily
feeding with 13.3 kcal/day/mouse of control diet
(AIN-93 M, Diet No. F05312; Bio-Serv, Flemington,
NJ). Treatment groups (36 mice) were shifted at the
same age to daily feeding with 13.3 kcal/day/mouse of
control diet mixed with simvastatin, simvastatin and
ramipril, ramipril, or candesartan and cold packed into
1 g pellets by Bio-Serv at the dosages shown in Table 1.
All mice were fed the same amount of food daily, after
the shift. The amount of food males of this strain would
eat at 12 months of age was determined by initially
feeding the mice ad libitum and reducing feeding week-
ly until approximately all the food was eaten daily. This
was defined as the control amount of food. Mice fed this
amount of food are neither fat nor lean and respond
robustly to 30 to 40 % CR with extended lifespan
[e.g., (Spindler et al. 2013b)]. The food was stored
moisture free at 4 °C until used. Food consumption
and mouse health were monitored at the time of feeding,
and any uneaten food was noted. With the exception
noted in the text, all food was eaten daily. The mice were
weighed bimonthly. The health of the mice was exam-
ined twice daily by laboratory staff, and weekly by a
veterinarian. Dead mice were stored at −20 °C until
necropsy. This study was approved by the Institutional
Animal Care and Use Committee at the University of
California, Riverside.
Statistical analysis of survival, body weight, and food
consumption
An unbalanced statistical design was utilized for logistic
and economic reasons (Jeske et al. 2014). The statistical
power for each group exceeded that required for a
Weibull survival analyses with a 75 % probability of
detecting a 10 % increase in mean lifespan with a 1 %
probability of a false positive (α ≤ 0.01) (Jeske et al.
2014). Weibull analyses are more stringent than the
Mantel-Cox (Mantel 1966; Peto and Peto 1972;
Harrington 2005) or Gehan-Breslow-Wilcoxon tests
(Wilcoxon 1945). We utilized Kaplan-Meier survival
curves and the Mantel-Cox and Gehan-Breslow-
Wilcoxon tests implemented in GraphPad Prism 5.01
to evaluate the significance of the treatments on lifespan.
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The weight of the mice was determined after an over-
night fast every 2 months. The significance of the dif-
ferences in body weights between the treated and con-
trol groups was judged using a linear mixed effects
model (Fitzmaurice et al. 2011; McCullagh and Nelder
1989), as described previously (Spindler et al. 2013a). In
brief, we modeled the mean response by a set of fixed
effects assumed to be shared by mice and a set of
random effects that are unique to a particular mouse.
Additionally, our model imposed a common intercept
since all mice were on the same diet at the time of the
first measurement. A Bayesian Information Criterion
(BIC) model selection criteria, a likelihood ratio test,
and an Akaike’s Information Criterion (AIC) model
selection criteria were used to determine significance
(Table 3). Food consumption was determined by total-
ing the amount eaten by each treatment group during a
2-month interval and dividing by number of mice alive
during the interval. This value was divided by the
amount eaten per mouse by the control group, calculated
similarly. The significance of the necropsy results was
determined using a Fisher’s exact test.
LC-MS/MS quantification of simvastatin in serum
Two methods were utilized for sample preparation for
LC-MS/MS analysis as described previously
(Spindler et al. 2012a). Briefly, for the first method,
200 μL of serum from a simvastatin-treated or un-
treated mouse was spiked with an internal standard of
1.8 nmol of lovastatin and extracted as described
(Zhao et al. 2000). In the second method, sample
extraction was performed as described in Lang et al.
(1986). The analysis of these extracts by LC-MS/MS
was performed as described previously (Spindler
et al. 2012a).
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